Subscription price for Moberg Pharma's warrants of series 2023:1 (TO 2) determined
Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") today announces that the subscription price for ordinary shares upon exercise of warrants of series 2023:1 is SEK 18.00 per ordinary share. The exercise period begins on June 5th, 2024, and runs until June 19th, 2024. The last day for trading in warrants of series 2023:1 on Nasdaq Stockholm is June 17th, 2024.
In 2023, Moberg Pharma carried out a rights issue of units which was oversubscribed to approximately 130%. Each unit consisted of one (1) ordinary share and one (1) warrant in Moberg Pharma. One (1) warrant entitles the holder to subscribe for one (1) new ordinary share in Moberg Pharma. The issue of units carried out in 2023 entailed potential financing based on upcoming capital needs and expected value-creating milestones (such as national approvals and ongoing market launch), minimized dilution, and attractive investment opportunities for existing and new investors in Moberg Pharma.
The strike price for the warrants was set at 70 percent of the volume-weighted average price for the Company's ordinary share on Nasdaq Stockholm during the period May 20th – May 31st, 2024. Thus, the strike price is SEK 18.00 per share.
"The warrants are part of our launch strategy for our drug MOB-015, which has recently been approved in 13 EU countries, and where our partner Allderma has already, in the first month with full marketing, taken the product to a market-leading position in Sweden under the brand name Terclara®" says Anna Ljung, CEO of Moberg Pharma.
Warrants of series 2023:1 in brief
Each warrant of series 2023:1 entitles the holder to subscribe for one (1) new ordinary share in the Company during the period June 5th, 2024, up to and including June 19th, 2024. The subscription price for subscription of ordinary shares with the support of warrants of series 2023:1 is SEK 18.00 (corresponding to 70 percent of the volume-weighted average price in the Company's ordinary share during the period from and including May 20th, 2024, up to and including May 31st, 2024). If all warrants are exercised for subscription of ordinary shares, the Company will receive approximately SEK 326.4 million in issue proceeds before transaction costs.
Upon exercise of all 18,134,519 warrants of series 2023:1, the Company's share capital will increase by approximately SEK 18,134,519.90.
Full terms and conditions for the warrants of series 2023:1 are available on Moberg Pharma’s website, https://www.mobergpharma.com/investors/exercise-warrants.
How the warrants are exercised:
Nominee-registered warrants:
Subscription and payment of new shares, by exercise of warrants, shall be made to the account-holding bank/nominee with which the warrants are registered. The subscription and payment shall be made in accordance with instructions from each such bank or nominee.
Directly registered warrants:
No payment instructions will be sent out. Subscription shall be made through simultaneous cash payment according to instructions on the subscription form. The warrants will then be replaced with interim shares pending registration with the Swedish Companies Registration Office. A subscription form with payment instructions is available on the Company's website, https://www.mobergpharma.com/investors/exercise-warrants, and on Vator Securities AB:s website www.vatorsecurities.se.
For additional information, please contact:
Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: [email protected]
Mark Beveridge, Vice President Finance, telephone: +46 76 805 82 88, e-mail: [email protected]
About this information
The information was submitted for publication at 8 p.m. CEST on May 31st, 2024, through the contact persons above.
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company's asset, MOB-015, is a novel topical treatment for onychomycosis with market approval in 13 EU countries. MOB-015 is available in Sweden under the brand name Terclara®. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the Company's shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).
Important information
The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Moberg Pharma. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in Moberg Pharma has only been made through the prospectus published by Moberg Pharma on August 14th, 2023.
